Sartorius Stedim Biotech Acquires Cellca
According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development.
Sartorius Stedim Biotech, an international supplier for the pharma and biotech industries, announced that it has acquired Cellca GmbH based in Laupheim, Germany.
Cellca was founded in 2005 and has approximately 30 employees. The company’s major customers are from the biopharmaceutical industry, including biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Cellca generated sales revenue of approximately EUR6 million in 2014.
According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development in addition to its two recent acquisitions of BioOutsource and TAP Biosystems.
Source: Sartorius
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
